York and North Yorkshire mayor opens up about mental health
A mayor has backed plans for a men's mental health "taskforce" after speaking about his struggles following the death of his father.Mayor of York and North Yorkshire David Skaith said he shut himself off after losing his father Bob in 2021, but said speaking about his feelings, sports and socialising helped him come to terms with his loss.Mr Skaith was speaking at a council meeting discussing plans to improve men's mental health in the region.He said: "Men will go running and go to the gym but how much are we actually doing to look after our head space too?"
The mayor, authority officials, NHS and charity representatives, and public health specialists discussed the plans, according to the Local Democracy Reporting Service.Mr Skaith said: "After losing my dad during the coronavirus pandemic I completely shut myself off and I stopped spending time with my family and friends."I wasn't doing anything to care for myself, it wasn't until I went back to sport and being back in that environment with other people started to help."The mayor said he hoped York and North Yorkshire could lead the way in shifting the dial on men's mental health.The meeting heard suicide was the biggest killer of men aged 50 and under, and that an estimated four in five men would experience some form of mental health issue during their lives.They discussed how mental health issues could be tackled locally, particularly given the amount of men working in traditionally male-dominated professions such as farming and the military.Officials suggested using sport, fitness and pitching mental health self-care to encourage men to become more conscious of the issue.
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
13 minutes ago
- Powys County Times
Alzheimer's blood test ‘can accurately pick up early symptoms'
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
The Independent
19 minutes ago
- The Independent
Early symptoms of Alzheimer's can now be detected with a blood test
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research from the Mayo Clinic. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity in picking up people with memory problems, and 82 per cent specificity in ruling out people without dementia. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use, and is much more convenient and cost-effective. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. The Blood Biomarker Challenge, supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research, aims to bring blood tests for dementia diagnosis to the NHS by 2029.
The Independent
20 minutes ago
- The Independent
NHS body revokes guidance advising hospitals to allow trans people to use chosen bathrooms
An NHS body has been criticised after it quietly withdrew guidance advising hospitals to allow trans people to use bathrooms and changing rooms of their choice. The NHS Confederation - which represents NHS trusts across the UK - confirmed to The Independent that it had removed the guidance from its website as it became 'dated' after April's Supreme Court ruling. The judgment found that the terms 'woman' and 'sex' in the Equality Act refer to a biological woman and biological sex, sparking disputes on how Britain should treat its equality policy. In the weeks after the ruling, the Equality and Human Rights Commission (EHRC) issued interim guidance which stated that trans women 'should not be permitted to use the women's facilities' in workplaces or public-facing services such as shops and hospitals'. The guidance is being legally challenged by trans-rights groups. The NHS Confederation said it had withdrawn its previously trans-inclusive advice and will issue new guidance when the EHRC updates its official Code of Practice. But trans rights groups have warned guidance on access to single-sex spaces is currently a legal 'minefield'. "The Supreme Court decision about the Equality Act doesn't mention toilets - not even once - and their provision is governed by separate legislation,' founder and executive director of Good Law Project, Jo Maugham KC, told The Independent. 'What the Supreme Court was very careful to say is that its judgment about the meaning of "woman" was solely about that word in the Equality Act. The 'toilets question' will be determined in judicial review proceedings that Good Law Project is filing today. 'For the NHS (or any other service provider) to take a position before the outcome is known is to invite lawsuits against it and risk wasting money that ought to be spent on patient care in the pursuit of ill-advised culture wars." TransActual, an organisation that supports the rights of trans people, said the development highlights the confusing implications of the ruling. "This decision may - or may not - be required as a result of the recent Supreme Court ruling,' a spokesperson said. 'However, what appears abundantly clear, based on advice from multiple lawyers and experts in this field, is that the supposed 'clarity' welcomed by the prime minister shortly after the ruling is, itself, in need of some clarification. "The law, based on a narrow interpretation of the Equality Act, may support this action. Equally, any future challenges on human rights grounds, which were not considered by the Supreme Court, may lead to a different outcome. It is a minefield. Organisations are damned if they act; damned if they do not. "We sympathise with the NHS Confederation and the position they find themselves in. Nonetheless, we believe they have reached the wrong conclusion - and that will, in turn, lead to significant harm to trans people needing medical care, as they now put off, or refuse treatment that may require a hospital stay." The NHS Confederation - which does not set official NHS policy - said its intention remains to provide its members with 'information that helps them best support their staff and patients', as it confirmed it had taken its previous guidance down. A spokesperson said: 'We will update and reinstate our guide as soon as the EHRC has updated its Code of Practice, which will need to be approved by the UK government, and when NHS England has then updated its guidance for what the changes mean for NHS organisations. 'The withdrawal of our guide does not change our explicit commitment to support our members to reduce the unacceptably high levels of bullying, abuse and discrimination at work that trans and non-binary staff and patients face.' On Monday, a hearing in a case against the EHRC over its consultation period for guidance in the wake of the Supreme Court ruling is set to go ahead. Human rights group Liberty is arguing the equalities watchdog had breached its statutory duties by implementing a six-week consultation period rather than a 12-week one. The EHRC will issue official post-ruling guidance after the consultation period.
